Iambic pairs proprietary AI models such as Enchant and NeuralPLexer with automated chemistry and biology labs to discover small-molecule drugs. Its stack shows a company moving from research into clinical stage: PyTorch, CUDA and Ray Tune sit alongside Medidata Rave, NONMEM, Phoenix WinNonlin and Veeva. Accelerating, senior-heavy hiring in research, quality and finance, plus Coupa adoption and QMS work, points to building GxP and procurement infrastructure.
Notable leadership hires: Immunology Director, Medical Director
Iambic is a privately held biotechnology company headquartered in San Diego, California, with 51–200 employees. It runs an integrated drug discovery platform that combines proprietary AI with scalable, automated laboratory experimentation. Its named AI technologies, Enchant and NeuralPLexer, predict multimodal endpoints to support discovery and clinical development. The company has advanced a drug candidate into the clinic and maintains a preclinical small-molecule pipeline. It hires in the United States and the United Kingdom.
Iambic uses Python, PyTorch, CUDA, Docker, Kubernetes, AWS, Weights & Biases and FastAPI for AI work, plus Medidata Rave, NONMEM, Phoenix WinNonlin, Veeva and NetSuite for clinical and finance operations.
Yes. Hiring is accelerating and centers on research, with additional roles in data, engineering, finance, quality and manufacturing. Most roles are senior or director level, including Immunology Director and Medical Director.
Iambic is headquartered in San Diego, California, and hires in the United States and the United Kingdom.
Other companies in the same industry, closest in size
Iambic's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.
